The global gamma globulins market is anticipated to grow at a CAGR of nearly XX% during the forecast period (2021-2027). The major factor contributing to the growth of the global gamma globulin market include the rising geriatric population and increasing numbers of hemophilic patients. According to the World Population Prospects 2019, by United Nation Population Division, approximately 9.32% of the total population in 2019 was over 65 years of age. According to the study published by Annals of Internal Medicine in September 2019, the prevalence of hemophilia was 3 times greater than the estimated numbers till September 2019. Approximately 1,125,000 men globally suffer from inherited bleeding disorders. 17.1 cases per 100,000 males were suffering from all severities of hemophilia A, 6.0 cases per 100,000 males were suffering from severe hemophilia A, 3.8 cases per 100,000 males were suffering from all severities of hemophilia B, and 1.1 cases per 100,000 males were suffering from severe hemophilia B. Moreover, the rise in the prevalence of hypogammaglobulinemia and chronic inflammatory demyelinating polyneuropathy (CIDP) will propel the growth of the market. 

Gamma globulins are the globulin that may be differentiated from other globulins on a serum protein electrophoresis by their position on the gel. Immunoglobulins (antibodies) are the most important gamma globulins, although some gamma globulins are not immunoglobulins and other immunoglobulins are not gamma globulins. Antibodies are produced in gamma globulin’s in humans and some other mammals. Due to the inability to build appropriate immunity to infectious diseases, individuals who lack gamma globulin (hypogammaglobulinemia) or have an insufficient supply of it (agammaglobulinemia)have repeated infections.

The key players contributing to the growth of the global gamma globulins market by adopting various strategies such as product launches and developments, mergers and acquisitions, partnerships, and agreements, include Grifols, S.A., Merck KGaA, Takeda Pharmaceutical Co. Ltd., Bio Products Laboratory, OCTAPHARMA Pharmazeutika Produktionsges.m.b.H, among others. For instance, in September 2019, the US FDA approved GamaSTAN, a human immunoglobulin by Grifols, S.A. for the treatment of patients suffering from hepatitis A and measles.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered- 

o By Product

o By Application

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape- Grifols, S.A., Merck KGaA, Takeda Pharmaceutical Company Limited, Bio Products Laboratory, OCTAPHARMA Pharmazeutika Produktionsges.m.b.H, among others.
  

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Gamma Globulin Market- Segmentation

By Product

• Lyophilized powder
• Injection

By Application

• Neurological and neuromuscular disease treatment
• Central nervous system disease treatment
• Peripheral nerves disease treatment
• Neuromuscular junction and muscles disease treatment

Global Gamma Globulin Market - Segmentation by region